Peter Attia· MD
now we can talk about nafl or i prefer the term metabolic associated fatty liver disease methyl d that's going to be the most common cause of liver disease liver inflammation end-stage liver disease and liver cancer
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
now we can talk about nafl or i prefer the term metabolic associated fatty liver disease methyl d that's going to be the most common cause of liver disease liver inflammation end-stage liver disease and liver cancer
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.